# National Institute of Allergy and Infectious Diseases (NIAID): Phase 1 study in Tuberculosis (116 participants)

**Score:** 40/100

| Field | Value |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sponsor type | NIH |
| Study | A Clinical Study of the HCMV-TB Vaccine Candidate VIR-1778 in Healthy Adults |
| NCT ID | NCT07818824 |
| Phase | Phase 1 |
| Status | not yet recruiting |
| Conditions | Tuberculosis |
| Intervention types | biological, other |
| Target enrollment | 116 |
| Site countries | Peru |
| Posted | 2026-09-14 |
| Planned start | 2026-11-06 |
| Event | Newly registered study |
| Event date | 2026-09-14 |

## Why this score
- 116 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07818824). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.